Andrew Joe Net Worth

Andrew Joe biography

Dr. Andrew Joe serves as Chief Medical Officer of the Company. Dr. Joe oversees all clinical and regulatory strategy and activities at Merus. He brings over 20 years of experience in clinical drug development and translational research within industry and academic medicine. Dr. Joe most recently led the immuno-oncology program at Sanofi, which included co-development of LIBTAYO ® (cemiplimab-rwlc) with Regeneron in skin, lung and other cancers. Previously at Merck Sharp & Dohme Corp., he led the KEYTRUDA ® (pembrolizumab) New Indications Development Team in obtaining the first tumor/histology-agnostic drug approval in Microsatellite Instability-High (MSI-H) cancer, and the first immuno-oncology drug approval in a gynecological malignancy (cervical cancer). Dr. Joe also played key roles at Novartis in the global approval of Zykadia ® (ceritinib) in ALK-positive lung cancer and at Roche in the global approval of ZELBORAF ® (vemurafenib) in BRAF-mutant metastatic melanoma. Dr. Joe is an Assistant Professor of Medicine at Columbia University Irving Medical Center. He received B.S. degrees in chemistry and biology from the Massachusetts Institute of Technology and an M.D. from the Mount Sinai School of Medicine.

What's Andrew Joe's mailing address?

Andrew's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.

Insiders trading at Merus N.V

Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., eCorp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.

What does Merus N.V do?

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Merus N.V executives and stock owners

Merus N.V executives and other stock owners filed with the SEC include:

• Hui Liu,
  Chief Business Officer and Head of Merus U.S.
• Dr. Sven Ante Lundberg M.D.,
  CEO, Pres, Principal Financial Officer & Exec. Director
• Peter B. Silverman J.D.,
  Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal
• Hui Liu,
  Chief Bus. Officer, Exec. VP & Head of Merus U.S.
• Alexander Bakker,
  Chief Development Officer
• Peter Silverman,
  General Counsel, Chief Intellectual Property Officer and Head of US Legal
• John de Kruif,
  Chief Technology Officer
• Sven Lundberg,
  President, Chief Executive Officer, Principal Financial Officer, Executive Director
• Anand Mehra,
  Non-Executive Independent Chairman of the Board
• Andrew Joe,
  Chief Medical Officer
• Paolo Pucci,
  Non-Executive Independent Director
• Victor Sandor,
  Non-Executive Independent Director
• Jillian Connell,
  Investor Relations & Corporate Communications
• Leonard Kanavy,
  Non-Executive Independent Director
• Gregory Perry,
  Independent Non-Executive Vice Chairman of the Board
• Mark Iwicki,
  Non-Executive Independent Director
• Shannon Campbell,
  Exec. VP & Chief Commercial Officer
• Dr. Cecile A.W. Geuijen Ph.D.,
  Chief Scientific Officer
• Anne Noordzij,
  Sec.
• Dr. Ellen Broug,
  Exec. Director of IP & Sec.
• Dr. Andrew Joe M.D.,
  Chief Medical Officer
• Alexander Berthold Hendrik Bakker Ph.D.,
  Chief Devel. Officer & Sr. VP
• Cornelis Adriaan de Kruif Ph.D.,
  CTO & Sr. VP
• Dr. Hennie Hoogenboom,
  Co-Founder and Scientific Advisor
• Partners L P/Ilbiotechnolog...,
  
• Lex Bakker,
  SVP, Chief Development Officer
• Mark Throsby,
  EVP & Chief Scientific Officer
• Partners L P/Ilbiotechnolog...,
  
• Corp Incyte,
  10% owner
• Cecile A W Geuijen,
  SVP & Chief Scientific Officer
• Jason Haddock,
  
• Maxine Gowen,
  
• Len Kanavy,
  
• Harry Shuman,
  VP Controller, PAO
• Fabian Zohren,
  Chief Medical Officer